Human plasminogen kringle 1-5 inhibits angiogenesis and induces thrombomodulin degradation in a protein kinase A-dependent manner

Journal of Molecular and Cellular Cardiology

Volumn 63, Issue , 2013, Pages 79-88

  Cho, Chia Fong ^a   Chen, Po Ku ^a   Chang, Po Chiao ^a   Wu, Hau Lin ^a   Shi, Guey Yueh ^a  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

Author keywords

Angiogenesis; Kringle 1 5; Protein kinase A; Thrombomodulin

Indexed keywords

CYCLIC AMP DEPENDENT PROTEIN KINASE; KRINGLE 1 5; PLASMINOGEN; THROMBOMODULIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIANGIOGENIC ACTIVITY; ARTICLE; CELL MIGRATION; CONTROLLED STUDY; DOWN REGULATION; ENDOTHELIUM CELL; ENZYME ACTIVITY; GENE OVEREXPRESSION; INTERNALIZATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; UBIQUITINATION;

ANGIOGENESIS; KRINGLE 1-5; PROTEIN KINASE A; THROMBOMODULIN;

ANIMALS; CATTLE; CELL LINE; CELL MOVEMENT; CYCLIC AMP-DEPENDENT PROTEIN KINASES; ENDOTHELIAL CELLS; HUMANS; NEOVASCULARIZATION, PHYSIOLOGIC; PEPTIDE FRAGMENTS; PLASMINOGEN; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN BINDING; PROTEIN INTERACTION DOMAINS AND MOTIFS; PROTEIN STABILITY; PROTEIN TRANSPORT; PROTEOLYSIS; SIGNAL TRANSDUCTION; THROMBOMODULIN; UBIQUITINATION;

EID: 84881496707     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2013.07.009     Document Type: Article

References (39)

1. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995, 1:27-31.
2. Folkman J., Shing Y. Angiogenesis. J Biol Chem 1992, 267:10931-10934.
3. O'Reilly M.S., Holmgren L., Shing Y., Chen C., Rosenthal R.A., Moses M., et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994, 79:315-328.
4. Gately S., Twardowski P., Stack M.S., Patrick M., Boggio L., Cundiff D.L., et al. Human prostate carcinoma cells express enzymatic activity that converts human plasminogen to the angiogenesis inhibitor, angiostatin. Cancer Res 1996, 56:4887-4890.
5. Gately S., Twardowski P., Stack M.S., Cundiff D.L., Grella D., Castellino F.J., et al. The mechanism of cancer-mediated conversion of plasminogen to the angiogenesis inhibitor angiostatin. Proc Natl Acad Sci U S A 1997, 94:10868-10872.
6. O'Mahony C.A., Seidel A., Albo D., Chang H., Tuszynski G.P., Berger D.H. Angiostatin generation by human pancreatic cancer. J Surg Res 1998, 77:55-58.
7. Morikawa W., Yamamoto K., Ishikawa S., Takemoto S., Ono M., Fukushi J., et al. Angiostatin generation by cathepsin D secreted by human prostate carcinoma cells. J Biol Chem 2000, 275:38912-38920.
8. Westphal J.R., Van't Hullenaar R., Geurts-Moespot A., Sweep F.C., Verheijen J.H., Bussemakers M.M., et al. Angiostatin generation by human tumor cell lines: involvement of plasminogen activators. Int J Cancer 2000, 86:760-767.
9. Soff G.A. Angiostatin and angiostatin-related proteins. Cancer Metastasis Rev 2000, 19:97-107.
10. Hatton M.W., Southward S.M., Ross B.L., Legault K., Marien L., Korbie D., et al. Angiostatin II is the predominant glycoform in pleural effusates of rabbit VX-2 lung tumors. J Lab Clin Med 2002, 139:316-323.
11. Basile D.P., Fredrich K., Weihrauch D., Hattan N., Chilian W.M. Angiostatin and matrix metalloprotease expression following ischemic acute renal failure. Am J Physiol Renal Physiol 2004, 286:F893-F902.
12. Peeters C.F., de Geus L.F., Westphal J.R., de Waal R.M., Ruiter D.J., Wobbes T., et al. Decrease in circulating anti-angiogenic factors (angiostatin and endostatin) after surgical removal of primary colorectal carcinoma coincides with increased metabolic activity of liver metastases. Surgery 2005, 137:246-249.
13. Soff G.A., Wang H., Cundiff D.L., Jiang K., Martone B., Rademaker A.W., et al. In vivo generation of angiostatin isoforms by administration of a plasminogen activator and a free sulfhydryl donor: a phase I study of an angiostatic cocktail of tissue plasminogen activator and mesna. Clin Cancer Res 2005, 11:6218-6225.
14. Yamahara K., Min K.D., Tomoike H., Kangawa K., Kitamura S., Nagaya N. Pathological role of angiostatin in heart failure: an endogenous inhibitor of mesenchymal stem-cell activation. Heart 2009, 95:283-289.
15. Chen J.S., Hwang J.C., Chang L.C., Wu C.C., Lin Y.F. Attributes of antiangiogenic factor plasminogen kringle 5 in glomerulonephritis. Arch Pathol Lab Med 2010, 134:1804-1812.
16. Drenberg C.D., Saunders B.O., Wilbanks G.D., Chen R., Nicosia R.F., Kruk P.A., et al. Urinary angiostatin levels are elevated in patients with epithelial ovarian cancer. Gynecol Oncol 2010, 117:117-124.
17. Cao R., Wu H.L., Veitonmaki N., Linden P., Farnebo J., Shi G.Y., et al. Suppression of angiogenesis and tumor growth by the inhibitor K1-5 generated by plasmin-mediated proteolysis. Proc Natl Acad Sci U S A 1999, 96:5728-5733.
18. Tarui T., Miles L.A., Takada Y. Specific interaction of angiostatin with integrin alpha(v)beta(3) in endothelial cells. J Biol Chem 2001, 276:39562-39568.
19. Troyanovsky B., Levchenko T., Mansson G., Matvijenko O., Holmgren L. Angiomotin: an angiostatin binding protein that regulates endothelial cell migration and tube formation. J Cell Biol 2001, 152:1247-1254.
20. Moser T.L., Stack M.S., Asplin I., Enghild J.J., Hojrup P., Everitt L., et al. Angiostatin binds ATP synthase on the surface of human endothelial cells. Proc Natl Acad Sci U S A 1999, 96:2811-2816.
21. Suzuki K., Kusumoto H., Deyashiki Y., Nishioka J., Maruyama I., Zushi M., et al. Structure and expression of human thrombomodulin, a thrombin receptor on endothelium acting as a cofactor for protein C activation. EMBO J 1987, 6:1891-1897.
22. Esmon C.T. The regulation of natural anticoagulant pathways. Science 1987, 235:1348-1352.
23. Van de Wouwer M., Conway E.M. Novel functions of thrombomodulin in inflammation. Crit Care Med 2004, 32:S254-S261.
24. Moore K.L., Esmon C.T., Esmon N.L. Tumor necrosis factor leads to the internalization and degradation of thrombomodulin from the surface of bovine aortic endothelial cells in culture. Blood 1989, 73:159-165.
25. Conway E.M., Rosenberg R.D. Tumor necrosis factor suppresses transcription of the thrombomodulin gene in endothelial cells. Mol Cell Biol 1988, 8:5588-5592.
26. Han H.S., Wu H.L., Lin B.T., Shi C.S., Shi G.Y. Effect of thrombomodulin on plasminogen activation. Fibrinolysis Proteol 2000, 14:221-228.
27. Shi C.S., Shi G.Y., Hsiao S.M., Kao Y.C., Kuo K.L., Ma C.Y., et al. Lectin-like domain of thrombomodulin binds to its specific ligand Lewis Y antigen and neutralizes lipopolysaccharide-induced inflammatory response. Blood 2008, 112:3661-3670.
28. Huang H.C., Shi G.Y., Jiang S.J., Shi C.S., Wu C.M., Yang H.Y., et al. Thrombomodulin-mediated cell adhesion: involvement of its lectin-like domain. J Biol Chem 2003, 278:46750-46759.
29. Gavard J., Gutkind J.S. VEGF controls endothelial-cell permeability by promoting the beta-arrestin-dependent endocytosis of VE-cadherin. Nat Cell Biol 2006, 8:1223-1234.
30. Maruyama I., Majerus P.W. The turnover of thrombin-thrombomodulin complex in cultured human umbilical vein endothelial cells and A549 lung cancer cells. Endocytosis and degradation of thrombin. J Biol Chem 1985, 260:15432-15438.
31. Satoh M., Kidokoro K., Ozeki M., Nagasu H., Nishi Y., Ihoriya C., et al. Angiostatin production increases in response to decreased nitric oxide in aging rat kidney. Lab Invest 2013, 93:334-343.
32. Wu T., Du Y., Han J., Singh S., Xie C., Guo Y., et al. Urinary angiostatin - a novel marker of renal pathology chronicity in lupus nephritis. Mol Cell Proteomics 2013, 12:1170-1179.
33. Lee T.Y., Muschal S., Pravda E.A., Folkman J., Abdollahi A., Javaherian K. Angiostatin regulates the expression of antiangiogenic and proapoptotic pathways via targeted inhibition of mitochondrial proteins. Blood 2009, 114:1987-1998.
34. Kilianova Z., Basora N., Kilian P., Payet M.D., Gallo-Payet N. Human melanocortin receptor 2 expression and functionality: effects of protein kinase A and protein kinase C on desensitization and internalization. Endocrinology 2006, 147:2325-2337.
35. Liu F., Verin A.D., Borbiev T., Garcia J.G. Role of cAMP-dependent protein kinase A activity in endothelial cell cytoskeleton rearrangement. Am J Physiol Lung Cell Mol Physiol 2001, 280:L1309-L1317.
36. Hsu Y.Y., Shi G.Y., Kuo C.H., Liu S.L., Wu C.M., Ma C.Y., et al. Thrombomodulin is an ezrin-interacting protein that controls epithelial morphology and promotes collective cell migration. FASEB J 2012, 26:3440-3452.
37. Dransfield D.T., Bradford A.J., Smith J., Martin M., Roy C., Mangeat P.H., et al. Ezrin is a cyclic AMP-dependent protein kinase anchoring protein. EMBO J 1997, 16:35-43.
38. Conway E.M., Nowakowski B., Steiner-Mosonyi M. Thrombomodulin lacking the cytoplasmic domain efficiently internalizes thrombin via nonclathrin-coated, pit-mediated endocytosis. J Cell Physiol 1994, 158:285-298.
39. Isermann B., Hendrickson S.B., Zogg M., Wing M., Cummiskey M., Kisanuki Y.Y., et al. Endothelium-specific loss of murine thrombomodulin disrupts the protein C anticoagulant pathway and causes juvenile-onset thrombosis. J Clin Invest 2001, 108:537-546.